Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Table 3 Discontinuation and switching rates for responders and non-responders [8 and Interviews with clinical experts]

	Responders		Non-responders
	2 year	4-weekly rate	2 year	4-weekly rate
Discontinuation rates
FDC tablet solifenacin 6 mg + TOCAS	43.0%	0.023	53.0%	0.031
Tolterodine + tamsulosin	59.8%	0.037	69.8%	0.049
Switching rates
FDC tablet solifenacin 6 mg + TOCAS	15.3%	0.007	15.3%	0.007
Tolterodine + tamsulosin	23.3%	0.011	23.3%	0.011

FDC, fixed-dose combination; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.

ISSN: 1471-2490